A blood test clue to unmask lipedema?

NCT ID NCT07787234

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study asks whether standard blood-based inflammation markers can distinguish lipedema from ordinary obesity and reflect how severe the condition is. Researchers will compare these markers in women with lipedema, women with obesity matched by body mass index, and healthy controls. No new treatments or invasive tests are involved—only existing lab data and, for lipedema patients, ultrasound and symptom questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If certain inflammation markers prove higher in lipedema and track with severity, they could become simple blood tests to help diagnose and monitor the condition.
What could go wrong
This is an observational study using existing lab data, so it cannot prove cause and effect. The markers may overlap with obesity-related inflammation, limiting their distinct usefulness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

192 people

The number who actually took part.

Started

Jun 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult female patients who presented to our hospital's Physical Medicine and Rehabilitation outpatient clinic and were clinically diagnosed with lipedema. The control group will consist of healthy female individuals evaluated at the same center who do not have a diagnosis of lipedema or lymphedema and have similar age characteristics. Sample size analysis will be performed using the G\*Power 3.1 program. Since the primary endpoint of the study is defined as the difference in SII between the lipedema and control groups, the comparison of the means of three independent groups will be the basis. In a two-tailed analysis, with Cohen's d = 0.60 effect size, alpha error level 0.05, and power 80%, 64 participants per group, totaling 192 participants, are required.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Inclusion Criteria (Patient Group) 1. Diagnosis of lipedema 2. Female patients aged 18-65 years 3. Literacy 4. Signing the informed consent form to participate in the study 2\. Inclusion Criteria (Obese-Overweight Control Group) 1. Female patients aged 18-65 years 2. Age and BMI matched with patients with lipedema 3. Literacy 4. Signing the informed consent form to participate in the study 3\. Inclusion criteria (healthy control group) 1. Being female, aged 18-65 2. BMI \<25 3. Being literate 4. Having signed the informed consent form by agreeing to participate in the study Exclusion Criteria: 1. Being under 18 or over 65 years of age 2. Acute infection, autoimmune/rheumatological disease, malignancy, hematological disease, receiving steroid/immunosuppressive treatment 3. Pregnancy 4. Peripheral artery disease 5. Severe cardiopulmonary failure (stage 3-4) 6. Systemic diseases such as uncontrolled hypertension and diabetes 7. Presence of cognitive impairment, hearing loss, communication difficulties that would hinder understanding of questionnaires and protocols

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflamation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Physical Medicine and Rehabilitation, Health Sciences University Sultan Abdulhamid Han Training and Research Hospital

    Istanbul, Uskudar, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.